• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
ZHENG Yan,LI Jiaying,YANG Yong,CHEN Zhen.Research progress of targeted therapy for chronic myeloid leukemia with Bcr-AblT315I mutation[J].Journal Of Pharmaceutical Research,2017,36(2):96-98[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 4135times   Download 3483次 QR Code for this article
Scan with your phone!
Bcr-AblT315I突变慢性髓系白血病靶向治疗的研究进展
郑燕1,李佳莹1,杨勇2,陈真1
Font:Larger+|Default|Smaller-
(1.中国药科大学药学医学基础实验教学中心,江苏 南京 211198;2.中国药科大学药物科学研究院,江苏 南京 211198)
摘要:
慢性髓细胞白血病(Chronic Myeloid Leukemia,CML)是一种自我更新的造血干细胞恶性增殖肿瘤。第一代酪氨酸激酶抑制剂伊马替尼的问世,为慢性髓细胞白血病患者带来了福音,但随之后来的耐药是一个巨大的挑战,尤其是Bcr-AblT315I突变引发的耐药程度最高。目前已有多种针对T315I突变的靶向治疗药物的研究,包括已上市的Ponatinib等,本文就近年来针对T315I突变的靶向治疗药物做一综述。
关键词:  慢性髓系白血病  Bcr-AblT315I突变  伊马替尼耐药  靶向治疗
DOI:10.13506/j.cnki.jpr.2017.02.010
基金项目:
Research progress of targeted therapy for chronic myeloid leukemia with Bcr-AblT315I mutation
ZHENG Yan1,LI Jiaying1,YANG Yong2,CHEN Zhen1
(1.Pharmaceutical and Medical Basic Experiment Teaching Center,China Pharmaceutical University,Nanjing 211198,China;2.Institute of Pharmaceutical Science,China Pharmaceutical University, Nanjing 211198,China)
Abstract:
Chronic Myeloid Leukemia (CML) is a self-renewing hematopoietic stem cell malignancy.The advent of the first-generation tyrosine kinase inhibitor—Imatinib has brought the gospel to the CML patients.However,resistance to Imatinib remains a major challenge,especially the Bcr-AblT315I mutations that with the highest resistance.Fortunately,there are many of therapies targeting T315I mutations having been reported,including the currently marketed Ponatinib.This review focused on the research progress of targeted therapies of T315I mutation in recent years.
Key words:  Chronic Myeloid Leukemia  Bcr-AblT315I mutation  Imatinib-resistant  Targeted Therapy
Today's Visits:468    Total Visits:2383167
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.